Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  AJP - Renal Physiology

• Publication date

  2011-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1152/ajprenal.00729.2010PMID 21593184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

  2011cited by this paper
• Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR.

  2010cited by this paper
• Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome

  2009cited by this paper
• Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies.

  2009cited by this paper
• Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model.

  2009cited by this paper
• Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.

  2009cited by this paper
• GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

  2008cited by this paper
• More Choces Than Ever Before

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.

  2008cited by this paper
• NHE3 phosphorylation at serines 552 and 605 does not directly affect NHE3 activity.

  2007cited by this paper
• Regulatory binding partners and complexes of NHE3.

  2007cited by this paper
• Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.

  2007cited by this paper
• Glucagon-Like Peptide-1 Is Involved in Sodium and Water Homeostasis in Humans

  2006cited by this paper
• Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.

  2005cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.

  2005cited by this paper
• Use of phospho-specific antibodies to determine the phosphorylation of endogenous Na+/H+ exchanger NHE3 at PKA consensus sites.

  2005cited by this paper
• Biologic actions and therapeutic potential of the proglucagon-derived peptides

  2005cited by this paper
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

  2004cited by this paper
• Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells.

  2004cited by this paper
• Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

  2004cited by this paper
• Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

  2003cited by this paper
• Rapid microplate method for PAH estimation.

  2002cited by this paper
• Renal effects of glucagon-like peptide in rats.

  2002cited by this paper
• Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.

  2002cited by this paper
• Association of Na+-H+ Exchanger Isoform NHE3 and Dipeptidyl Peptidase IV in the Renal Proximal Tubule*

  2001cited by this paper
• Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

  2001cited by this paper
• S3226, a novel inhibitor of Na+/H+ exchanger subtype 3 in various cell types

  1998cited by this paper
• Enteroglucagon.

  1997cited by this paper
• Monoclonal antibodies for high-resolution localization of NHE3 in adult and neonatal rat kidney.

  1997cited by this paper
• Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update.

  1995cited by this paper
• Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.

  1993cited by this paper
• Diabetes mellitus and hypertension.

  1992cited by this paper
• Detection of specific mRNAs in single nephron segments by use of the polymerase chain reaction.

  1990cited by this paper
• A standard nomenclature for structures of the kidney

  1988cited by this paper
• A standard nomenclature for structures of the kidney. The Renal Commission of the International Union of Physiological Sciences (IUPS).

  1988cited by this paper
• Diabetes Mellitus and Hypertension State of the Art Lecture

  1988cited by this paper
• Energy-dependence of phlorizin binding to isolated renal microvillus membranes

  1978cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

  1967cited by this paper
• MICROPUNCTURE STUDY OF RENAL POTASSIUM EXCRETION IN THE RAT.

  1964cited by this paper

• GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.

  2026cites this paper
• In vivo functional profiling and structural characterization of the human GLP1R A316T variant.

  2026cites this paper
• A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist

  2025cites this paper
• Blood pressure effects of SGLT2 inhibitors and GLP-1 receptor agonists: Mechanisms, trial evidence and Real-world data.

  2025cites this paper
• Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document

  2025cites this paper
• Physical association of NHE3 and SGLT2 mediated by accessory proteins in the renal proximal tubule.

  2025cites this paper
• Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials

  2025cites this paper
• The relationship between excess sodium intake and metabolic syndrome: Worth consideration?

  2025cites this paper
• GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes

  2025cites this paper
• Diversity of pleiotropic effects of semaglutide: From potential mechanisms to real clinical outcomes

  2025cites this paper
• Plasma volume status in type 2 diabetes and its association with antidiabetic therapy

  2025cites this paper
• Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

  2025cites this paper
• Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists

  2025cites this paper
• Hypokalemia Requiring Hospitalization After Taking Semaglutide Injections

  2025influential citation
• Role of obesity in chronic kidney disease progression

  2025cites this paper
• Insights into the Mechanism of Action of Tirzepatide: A Narrative Review

  2025cites this paper
• Unique Role of Proximal Tubule Dipeptidyl Peptidase 4 on Blood Pressure, Renal Sodium Handling, and Na+/H+ Exchanger Isoform 3 Phosphorylation

  2025cites this paper
• GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications.

  2025cites this paper
• Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight

  2025cites this paper
• Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.

  2025cites this paper
• The role of GLP1R gene polymorphism in diabetic nephropathy in patients with type 2 diabetes

  2025cites this paper
• Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials.

  2025cites this paper
• GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation

  2025cites this paper
• Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists.

  2025cites this paper
• Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)—Disproportionality Study

  2025cites this paper
• Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review

  2025cites this paper
• THERAPEUTIC POTENTIAL OF BUCHHOLZIA CORIACEA IN MODULATING HAEMATOLOGICAL AND ELECTROLYTE PARAMETERS IN DIABETIC RATS

  2025cites this paper
• Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus

  2024cites this paper
• Incretin and glucagon receptor polypharmacology in chronic kidney disease

  2024cites this paper
• Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways

  2024cites this paper
• Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies

  2024cites this paper
• Transcriptomics of SGLT2-positive early proximal tubule segments in mice: response to type 1 diabetes, SGLT1/2 inhibition or GLP1 receptor agonism.

  2024cites this paper
• The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets

  2024cites this paper
• Variants in PPARD-GLP1R are related to diabetic kidney disease in Chinese Han patients with type 2 diabetes mellitus

  2024cites this paper
• Cyclic Adenosine Monophosphate Signaling in Chronic Kidney Disease: Molecular Targets and Therapeutic Potentials

  2024cites this paper
• The influence of insulin and incretin-based therapies on renal tubular transport

  2024cites this paper
• High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats

  2024cites this paper
• Impact of Proximal Tubule-Specific Deletion of Dipeptidyl Peptidase 4 on Blood Pressure, Renal Sodium Handling, and NHE3 Phosphorylation

  2024cites this paper
• In vivo functional profiling and structural characterisation of the human Glp1r A316T variant

  2024cites this paper
• GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism

  2024cites this paper
• GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences

  2024cites this paper
• Efeitos renais do Peptídeo 1 Semelhante ao Glucagon (GLP1): das bases moleculares a uma perspectiva farmacofisiológica

  2024cites this paper
• GLP-1-receptoragonisták szerepe a krónikus vesebetegségben

  2024cites this paper
• SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  2024cites this paper
• Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective

  2024cites this paper
• Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications

  2024cites this paper
• Glomerular hyperfiltration as a therapeutic target for CKD

  2024cites this paper
• GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.

  2024cites this paper
• A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists

  2024cites this paper
• Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management.

  2024cites this paper
• The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms.

  2023cites this paper
• Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease

  2023cites this paper
• Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs

  2023cites this paper
• Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release

  2023cites this paper
• Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors - is renal hemodynamics the key point?

  2023cites this paper
• Regulation of Na/H Exchanger Isoform 3 by Protein Kinase A in the Renal Proximal Tubule

  2023cites this paper
• Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.

  2023cites this paper
• GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes

  2023cites this paper
• Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease

  2023cites this paper
• Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study

  2023cites this paper
• SGLT-2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies.

  2023cites this paper
• Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives

  2023cites this paper
• Incretins and cardiovascular disease: to the heart of type 2 diabetes?

  2023cites this paper
• Effects of water-sodium balance and regulation of electrolytes associated with antidiabetic drugs.

  2023cites this paper
• GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions

  2022cites this paper
• Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation

  2022cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence

  2022cites this paper
• Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease

  2022cites this paper
• Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.

  2022cites this paper
• GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art

  2022cites this paper
• Effect of glucagon‐like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

  2022cites this paper
• Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.

  2022cites this paper
• Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure.

  2022cites this paper
• Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects

  2022cites this paper
• Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations

  2022cites this paper
• Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease

  2022cites this paper
• Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice

  2022cites this paper
• Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases

  2022cites this paper
• Hypothalamic GPCR Signaling Pathways in Cardiometabolic Control

  2021cites this paper
• Physiological Role of Intestinotropic Glucagon Like Peptides in Health and Disease

  2021cites this paper
• Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications.

  2021cites this paper
• Changes in the renal function after acute mercuric chloride exposure in the rat are associated with renal vascular endothelial dysfunction and proximal tubule NHE3 inhibition.

  2021cites this paper
• Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women

  2021cites this paper
• The Role of Gasotransmitters in Gut Peptide Actions

  2021cites this paper
• Cardiorenal Protection in Diabetic Kidney Disease

  2021cites this paper
• Comparative effectiveness of a glucagon-like peptide-1 receptor agonist versus a dipeptidyl peptide-4 inhibitor on kidney and cardiovascular outcomes in routine clinical practice.

  2021cites this paper
• Role of Renal Sympathetic Nerves in GLP‐1 (Glucagon‐Like Peptide‐1) Receptor Agonist Exendin‐4‐Mediated Diuresis and Natriuresis in Diet‐Induced Obese Rats

  2021cites this paper
• Agonistas Del Receptor Glp-1: Desde su Efecto Fisiologico en el Sistema Incretina Hasta du Rol en Enfermedad Renal Diabetica

  2021cites this paper
• Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System

  2021cites this paper
• Postprandial Increase in Glucagon-like Peptide-1 is Blunted in Severe Heart Failure.

  2020cites this paper
• GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in pre-hypertensive rats.

  2020cites this paper
• Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu.

  2020cites this paper
• Recent advances in understanding the role of glucagon-like peptide 1

  2020cites this paper
• Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

  2020cites this paper
• Using a reporter mouse to map known and novel sites of GLP-1 receptor expression in peripheral tissues of male mice.

  2020cites this paper
• Cardiorenal effects of newer antidiabetic agents

  2020cites this paper
• A role for the tubular Na+-H+-exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.

  2020cites this paper
• Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.

  2020cites this paper
• Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control: Role of Proximal Tubule Na+/H+ Exchanger Isoform 3, Renal Angiotensin II, and Insulin Sensitivity.

  2020cites this paper
• Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics

  2020cites this paper